abstract |
The present invention relates to novel substituted 6- (2-hydroxybenzylamino) purine of formula (I) as polyspecific cyclin-dependent kinase inhibitors 2, 5, 7 and 9 and their use as medicaments in the treatment of diseases, particularly those that combine cellular hyperproliferation with inflammatory diseases. The invention further includes pharmaceutical compositions comprising substituted 6- (2-hydroxybenzylamino) purines. |